BioTuesdays

Tag - Parkinson’s

Dawson James starts Anavex at buy: PT $16

Dawson James initiated coverage of Anavex Life Sciences (NASDAQ:AVXL) with a “buy” rating and $16 price target. The stock closed $2.54 on July 23. Anavex is pioneering a new treatment in CNS diseases like...

Subscribe

Sign up to our weekly BioTuesdays newsletter.